Openfund

CORDIS · SCREEN4CARE

Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies

Код
SCREEN4CARE
Програма
H2020
Процедура
IMI2-2020-23-05
Статус
SIGNED
Период
01.10.2021 – 30.09.2026
Обща стойност (целият консорциум)26 247 174 €
Принос на ЕС (целият консорциум)11 938 569 €
Принос на ЕС за българските участници226 721 €

Официални данни · CORDIS · синхронизирано 18.10.2026 03:29 · официален запис

Участници

ОрганизацииРоляДържаваБезвъзмездна помощ
UNIVERSITA DEGLI STUDI DI FERRARAкоординаторIT691 786 €
UNIVERSITAETSKLINIKUM FREIBURGучастникDE1 119 459 €
CHARITE - UNIVERSITAETSMEDIZIN BERLINучастникDE1 049 100 €
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTSучастникDE931 361 €
OSPEDALE PEDIATRICO BAMBINO GESUучастникIT753 848 €
EURORDIS - RARE DISEASES EUROPEучастникFR736 895 €
UPPSALA UNIVERSITETучастникSE675 785 €
UNIVERSITAET BERNучастникCH659 656 €
SYDDANSK UNIVERSITETучастникDK651 996 €
FINDZEBRA APSучастникDK493 646 €
UNIVERSITATSKLINIKUM ERLANGENучастникDE490 000 €
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBHучастникDE485 375 €
GNX DATA SYSTEMS LTDучастникIL392 000 €
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICOучастникES388 544 €
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINучастникIE373 014 €
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVучастникDE342 528 €
SBA RESEARCH GEMEINNUTZIGE GMBHучастникAT309 750 €
SITEM-INSEL AGучастникCH308 218 €
RESEARCH INSTITUTE AG & CO KGучастникAT273 410 €
LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNGучастникAT203 040 €
CENTRE HOSPITALIER REG UNIVERSITAIRE DIJONучастникFR142 861 €
CONSORZIO FUTURO IN RICERCAучастникIT120 000 €
BULGARIAN ASSOCIATION FOR PERSONALIZED MEDICINEучастникBG113 471 €
BULGARIAN ASSOCIATION FOR PROMOTION OF EDUCATION AND SCIENCEучастникBG113 250 €
COPENHAGEN BUSINESS SCHOOLучастникDK62 106 €
UNIVERSITA DEGLI STUDI DI SIENAучастникIT56 045 €
FUNDACIO CENTRE DE REGULACIO GENOMICAучастникES1 425 €
PTC THERAPEUTICS INTERNATIONAL LIMITEDучастникIE0 €
UCB BIOPHARMAучастникBE0 €
PROQR THERAPEUTICS NVучастникNL0 €
TAKEDA PHARMACEUTICALS INTERNATIONAL AGучастникCH0 €
LYSOGENEучастникFR0 €
WALLAC OYучастникFI0 €
PFIZER LIMITEDучастникUK0 €
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENTучастникFR0 €
F. HOFFMANN-LA ROCHE AGучастникCH0 €
NOVARTIS PHARMA AGучастникCH0 €
ILLUMINA CAMBRIDGE LIMITEDучастникUK0 €
UNIVERSITATSKLINIKUM BONNучастникDE0 €
UNIVERZITA KARLOVAучастникCZ0 €
NOVO NORDISK A/SучастникDK0 €

Описание

In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general population, are affected by one of the 6,172 different rare diseases (RDs) of which 72% are genetic and 70% affect children. The path to diagnosis for people suffering from a RD is burdensome, often severely delayed by a diagnostic odyssey. Lack of timely diagnosis affects disease management, family planning, identification of potential beneficial treatments and / or clinical trials. This unacceptable situation does not meet the concept of equity for EU citizens, and requires rapid, structured, and cost-effective corrective actions. The Screen4Care (S4C) consortium will leverage the genomic and digital advent to develop and pilot genetic NBS and AI-guided symptom recognition algorithms, while accounting for all relevant legal, regulatory and ethical considerations. S4C aims to harmonize the results of existing efforts in a horizon scan, by looking at the totality of the available data resources, diagnostic algorithms, and other initiatives with similar ultimate goals.The genetic NBS will interrogate 1) currently treatable RDs (TREAT-map gene panel), 2) actionable RDs (ACT-map gene panel) in 18.000 new-borns in 3 EU countries (D, It, and Cz). Further, S4C will offer whole genome sequencing (WGS) to early symptomatic babies, tested negatively during panel-based NBS to identify known NBS-escaped RDs and novel genes/phenotypes. S4C will also provide two digital diagnosis support systems for RD on the basis of features and symptom complexes: 1) federated ML- and literature-evidence-based algorithm for continuous and automated screening of EHR and 2) meta symptom checker with virtual clinics for patients and HCP offering the possibility of increased accuracy of diagnosis and ongoing supports. Our ambitious goal is to evaluate the validity of our multi-pronged approach to shorten the time to diagnosis for all patients affect by RDs, improve value-based healthcare resource utilization, and hopefully reduce the suffering of millions of European citizens.

Официални данни · CORDIS · синхронизирано 18.10.2026 03:29 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).